ClinicalTrials.gg

Sinopharm clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 95 studies whose lead sponsor is Sinopharm or one of 6 companies grouped under it. 18 are recruiting or about to start. Per ClinicalTrials.gov, last updated Oct 28, 2026.

Our grouping of 6 registry names, not the registry’s. See them and correct one ↓

Compare Sinopharm with GlaxoSmithKline and Bavarian Nordic →

Pipeline: 12 programs

Each counted once: 12 with a study Sinopharm leads registered in the last two years.

  • Phase 1
  • Phase 2

5 from the earlier phases, besides the phase-3 view.

Program
Influenza virus split vaccine (0.7mL/vial)Phase 2 · 2 live · Influenza, Human☆ Track
SIBP-A16 injectionPhase 2 · 2 live · Premature Birth · primary completion Mar 2027☆ Track
Human Rabies Immunoglobulin (HRIG)Phase 2 · 1 live · Rabies☆ Track
MVA-SIBP low dosePhase 2 · 1 live · Mpox, Monkeypox · primary completion Feb 2027☆ Track
Recombinant herpes zoster vaccine with low-dose adjuvantPhase 2 · 1 live · Herpes Zoster☆ Track

7 more — sign in to see them all, free: with every program, filter by condition or phase and sort by first study or primary completion.

Not counted: 1 approved drug Sinopharm gives alongside its own in its studies — rabies vaccine (with Recombinant Human Rabies Virus Monoclonal Antibody Injection). Our rule: a drug many companies test, in every study Sinopharm led of it in the last two years beside a drug of its own.

“Registry” is the highest phase of Sinopharm’s own registered studies; Sinopharm’s own pipeline document is not read yet. “Primary completion” is the earliest date still ahead among its live studies when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced. Programs are read from ClinicalTrials.gov, joined across names by rules and decisions each recorded with its evidence.

What it is testing

The drugs Sinopharm’s studies test, most open studies first — 16 drugs with a page of their own. Each count opens the studies in search.

Open now Not open: under way, finished or stopped

Show 6 more

Coming up

5 of Sinopharm’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.

Phase 3 Other phases

  1. N’26
  2. 2D
  3. J’27
  4. 1F
  5. 1M
  6. 1A
  7. M
  8. J
  9. J
  10. A
  11. S
  12. O
  13. N

Add all 5 to your calendar (.ics) → With an account.

All 95 at a glance

Where each study is in its life, its phase and its countries. Each count opens them in search.

  • Open now1819%Recruiting 12 · Not yet recruiting 5 · Enrolling by invitation 1
  • Under way, not recruiting99%
  • Completed3840%
  • Status unknown or other3032%

Phase

  • Phase 430
  • Phase 128
  • Phase 222
  • Phase 320
  • Early Phase 11

Where

  • China80
  • United Arab Emirates7
  • Bahrain1
  • Hong Kong1
  • Egypt1
  • Jordan1

Over the years

  1. 09
  2. 10
  3. 11
  4. 12
  5. 13
  6. 14
  7. 15
  8. 16
  9. 17
  10. 18
  11. 19
  12. 20
  13. 2521
  14. 22
  15. 23
  16. 24
  17. 25
  18. 426

By the year each study started. 2026 so far in the lighter column.

Registry sponsor names on this page

Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.

Tell us about a missing company
No account needed. Please leave out personal details.

Each name exactly as ClinicalTrials.gov lists it, and how it relates to Sinopharm.

  • China National Biotec Group Company Limited
    Acquired — became part of Sinopharm, Nov 2010 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    37 studies →
  • Shanghai Institute Of Biological Products
    Acquired — became part of Sinopharm, Nov 2010 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    34 studies →
  • National Vaccine and Serum Institute, China
    Acquired — became part of Sinopharm, Nov 2010 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    13 studies →
  • Lanzhou Institute of Biological Products Co., Ltd
    Acquired — became part of Sinopharm, Nov 2010 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    7 studies →
  • Wuhan Institute of Biological Products Co., Ltd
    Acquired — became part of Sinopharm, Nov 2010 · source ↗
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    3 studies →
  • Sinopharm Wuhan Plasma-derived Biotherapies Co., Ltd.
    Subsidiary
    Something wrong?
    What is wrong with this name?
    No account needed. Please leave out personal details.
    1 study →

Focus areas

Conditions Sinopharm leads ten or more studies in, by study count. A broader condition is left out when almost all its studies are already in a narrower one listed here.

Studies

Recruiting first, then most recently updated. Showing 50 of 95. Browse all 95 →